Abstract
Patients with coronavirus disease 2019 (COVID-19) from novel coronavirus (SARS-CoV-2) infection may present with immune thrombocytopenia (ITP). Multisystem inflammatory syndrome in children (MIS-C) is a serious complication of SARS-CoV-2 causing systemic organ dysfunction. This case series presents the first reported cases of patients who developed ITP following MIS-C, while completing corticosteroid tapers. These patients responded to standard of care therapies for ITP and had appropriate platelet count recovery. We emphasize the importance of careful monitoring of those recovering from COVID-19 or MIS-C, to proactively identify clinical and laboratory abnormalities, in addition to long-term cardiovascular sequelae.
Keywords:
COVID-19; ITP; MIS-C; SARS-CoV-2; novel coronavirus.
MeSH terms
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
-
Aspirin / therapeutic use
-
COVID-19 / blood
-
COVID-19 / complications*
-
COVID-19 / therapy
-
Child
-
Disease Management
-
Glucocorticoids / therapeutic use
-
Humans
-
Infant
-
Male
-
Methylprednisolone / therapeutic use
-
Platelet Count
-
Prednisolone / therapeutic use
-
Purpura, Thrombocytopenic, Idiopathic / blood
-
Purpura, Thrombocytopenic, Idiopathic / etiology*
-
Purpura, Thrombocytopenic, Idiopathic / therapy
-
Systemic Inflammatory Response Syndrome / blood
-
Systemic Inflammatory Response Syndrome / complications*
-
Systemic Inflammatory Response Syndrome / therapy
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
Glucocorticoids
-
Prednisolone
-
Aspirin
-
Methylprednisolone
Supplementary concepts
-
pediatric multisystem inflammatory disease, COVID-19 related